幾丁聚醣對高血脂患者血脂質和礦物質的影響
Effect of dietary chitosan on the blood lipids profile and mineral status in hyperlipidemaic patients
中文摘要
本研究之目的是探討服用幾丁聚醣對高血脂症患者的血脂質和礦物質鈣、鎂以 及鐵之影響。對象為高血脂症患者，篩選標準為總膽固醇>200 mg/dL 以上或三 酸甘油酯>200 mg/dL。實驗設計共分成三組，每組 20 人，實驗組分別給予 300 毫克的水溶性幾丁聚醣或非水溶性幾丁聚醣之錠劑，每日三次，每次各兩片，另 一組為安慰劑組，皆於飯前服用，並按原飲食習慣攝食，實驗期間受試者必須停 止降血脂藥物。在實驗前、實驗第 4 週和第 8 週時，進行體位測量、採血分析及 尿液檢查，並於當週做 3 天飲食紀錄。結果發現，服用幾丁聚醣會顯著降低高血 脂症患者的血清總膽固醇和低密度脂蛋白膽固醇濃度，但對血清三酸甘油酯和高 密度脂蛋白膽固醇濃度沒有影響，服用幾丁聚醣也不會影響患者的血清鈣和血清 鎂濃度、尿鈣和尿鎂排泄量；服用水溶性幾丁聚醣 8 週後，會使血清運鐵蛋白
（transferrin）和平均紅血球紅色素（MCHC）濃度顯著下降。所有受試者於實 驗期間之總熱量和三大營養素攝取量與實驗前無差異。因此，服用幾丁聚醣不論 水溶性或非水溶性的八週後可顯著降低血清總膽固醇和低密度脂蛋白膽固醇濃 度，但服用水溶性幾丁聚醣會使血清運鐵蛋白和 MCHC 有下降的趨勢。
英文摘要
The aim of this study is to investigate the effects of dietary chitosan on the blood lipid profiles, serum calcium, serum magnesium, and serum iron status in hyperlipidemic patients who were serum total cholesterol > 200 mg/dL or triglycerides > 200 mg/dL.
The patients divided into three groups, two treatment groups administered
water-soluble chitosan or water-insoluble chitosan, and one placebo group, orally and received two tablets, three times a day before meals, for 8 weeks. Before the trial and at 4 and 8 weeks of treatment, anthropometric measurements and diet records and fasting blood were analyzed, and 24 hour urine samples were collected. Ingestion of chitosan significantly reduced serum total cholesterol and LDL-C levels after 4 weeks compared to baseline, and after 8 weeks serum triglyceride and HDL-C levels
compared to baseline did not change significantly. Significant reductions in mean corpuscular hemoglobin concentration (MCHC) and serum transferrin levels but still in normal range were observed after 8 weeks of water-soluble chitosan ingestion.
Serum calcium, serum magnesium, urinary calcium and magnesium excretion showed no significant difference among three groups. Chitosan might be effective treatment for hyperlipidemia patients but supplement of water-soluble chitosan reduce serum
transferrin and MCHC.
